RxDoctor Payments Data

Ryan Williams, PA

Physician Assistant · Big Spring, TXNPI 1073612164

Payments from drug & device makers

$321in general payments, 2019–2025

Across 17 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$140
  • Lilly USA, LLC$91
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$27
  • Boehringer Ingelheim$20
  • Novo Nordisk$15
  • Otsuka America Pharmaceutical, Inc.$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$321 in reported general payments places this provider in the 45th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$34,477
Medicare patients
131
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$40,380
FarxigaDapagliflozin Propanediol27$31,700
EliquisApixaban27$24,187
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$18,662
MounjaroTirzepatide13$18,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,067
MyrbetriqMirabegron12$6,169
Levemir FlexpenInsulin Detemir12$1,968
Levothyroxine Sodium128$1,534
Rosuvastatin Calcium100$1,440
SynthroidLevothyroxine Sodium16$994
Celecoxib23$919
Gabapentin57$912
Albuterol Sulfate HfaAlbuterol Sulfate41$883
Tamsulosin Hcl48$769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$40,38042 claims
Lilly USA, LLCMounjaro$91$18,07813 claims
GSKTrelegy Ellipta$12$13,06712 claims
AbbVieSynthroid$140$99416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Big Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →